Background

Acute promyelocytic leukaemia (APL) results from the reciprocal chromosomal translocation t(15;17)(q24;21) (PML–RARA gene fusion). We have formulated an oral, economical, and outpatient-based preparation of arsenic trioxide and shown that it is efficacious for newly diagnosed and relapsed APL. In this study, we aimed to define the epidemiological landscape of APL in Hong Kong and to assess the effect of oral arsenic trioxide therapy on patient outcomes.